|
Advised Addex Pharmaceuticals on two significant licences with Merck & Co Inc
|
|
Advised ALK-Abelló A/S on its co-promotion and licence agreements with Menarini
|
|
Advised ALK-Abelló A/S on its licence and development agreement with Schering Plough
|
|
Advised ALK-Abelló A/S on its recombinant allergen development agreement with Novozymes
|
|
Advised AstraZeneca on its strategic alliance with Cambridge Antibody Technology and the commercial and IP due diligence on the subsequent acquisition of a Cambridge Antibody Technology
|
|
Advised Cambridge Consultants on the licensing of inhaler technology to 3M
|
|
Advised Cellzome on a major strategic alliance with GSK
|
|
Advised Cowen Healthcare Royalty Partners on the IP aspects of their acquisition of AeternaZentaris royalty interest in Cetrotide
|
|
Advising EUSA Pharma on its acquisition of Taliska and French company, OPi
|
|
Advised Meda AB on its $392m acquisition of Valeant Pharmaceutical Inc.s Western and Eastern European and Middle Eastern businesses
|